Drugs / Lu AF28996
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT07513441 | Mar 2026 → May 2027 expected | Parkinson disease | H. Lundbeck A/S | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06337110 | Apr → May 2024 | — | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 1 | NCT06277609 | Feb → May 2024 | — | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 1 | NCT06004180 | Sep → Nov 2023 | Parkinson disease | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 1 | NCT04291859 | Feb 2020 → Oct 2025 | Parkinson disease | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 1 | NCT03565094 | May 2018 → Aug 2019 | — | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07514858 | Jul 2026 → Oct 2028 expected | Parkinson disease | H. Lundbeck A/S | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lu AF28996 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06277609 ↗ |
| Route | Oral | “single oral dose of Lu AF28996” NCT03565094 ↗ |